The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era

@article{Mocroft2006TheFO,
  title={The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era},
  author={Amanda Mocroft and James Neaton and Judith D. Bebchuk and S. Staszewski and F. Antunes and Brygida Knysz and Marc T. Law and Andrew N Phillips and Jens D. Lundgren},
  journal={Clinical Trials},
  year={2006},
  volume={3},
  pages={119 - 132}
}
  • Amanda Mocroft, James Neaton, +6 authors Jens D. Lundgren
  • Published in Clinical trials 2006
  • Medicine
  • Clinical Trials
  • Background Planning clinical-endpoint trials in patients with HIV remain difficult as long-term follow-up of many patients is required. Cohort studies of patients with HIV can provide key estimates of the likely disease progression, required sample size and follow-up. Objectives To verify the assumptions used in designing ESPRIT, a large randomized clinical trial assessing the clinical benefit of interleukin-2 treatment in patients with HIV infection, to use EuroSIDA to mimic the inclusion… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 17 REFERENCES

    Triple-nucleoside regiimetiis verSuS efavirenz-contairing regimens for the intitial treatmiient of HIV-1 inifectioin

    • RM Gullick, HJ Ribaudo, at. Shikurma CM et
    • N Enigi I AMe
    • 2004

    IParticipationi in research and access to experimental treiatments by 111V-infected patients

    • AL Gifford, WE Cunninghani, KC Heslin
    • N Erngi1 Med
    • 2002

    The evaluation of subcutan.eous proleuikin (interleukin-2) in a randomised international trial: ratioirale, design and methiods Cif ESPRIT

    • S Emery, DI Abrams, DA Cooper
    • onIt (tlin Trialls
    • 2002
    VIEW 2 EXCERPTS

    AIDS cicross Europe; 1994-1998: Trhe EuroSIDA study

    • A Mocroft, C Katlama, AM Johnson
    • 2000

    Evaluation of l-tlV- I immLtogen, an immunologic modifier, iidninistere(i to p.tients with HIV having 300 to 5149 x 10/1 CD4 cell counts

    • JO Kahn, DW Cheng, K Mayer, H Murray, S Lagakos
    • JAAfA
    • 2000
    VIEW 1 EXCERPT

    Participation in clinical trials amongst patients infected with HIV 1 in a single treatlent centre over 12 years

    • S Madge, A Mocroft, cli. Wilson D et
    • I-IV Medicine
    • 2000

    Efavirenz plus zidovudiine a-nd laTImivudine, efavirenz plus indinavir plus zidovudine and lamivudirie in the treatment of HIV-1 infectiotn in adUlts

    • S Staszewski, J Moralis-Ramirez, KT Tashima
    • N Eng/ I Mecd
    • 1999

    Antiretroviral therapy for HlV infection

    • CCJ Carpenter, MA Fischl, SM Hammer
    • Updated recomendaitions of the International AIDS Society-UISA panel
    • 1998